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Abstract 
Background: Several studies have reported increased incidence trends of malignant gliomas 
in the late 1900’s with a plateau in the 2000’s, but also some recent increases have been 
reported. The purpose of our study was to analyze incidence trends of malignant gliomas in 
Finland by morphology and tumor location. 
Materials and Methods: Data on 4,730 malignant glioma patients were obtained from case 
notifications to the nationwide, population-based Finnish Cancer Registry, and less detailed 
data on 3,590 patients up to 2016. Age-standardized incidence rates and average annual 
percent changes in the incidence rates were calculated by histological subtype and tumor 
location. 
Results: The incidence rate of gliomas was 7.7/100,000 in 1990–2006 and 7.3 in 2007–2016. 
The incidence of all gliomas combined was stable during both study periods, with no 
departure from linearity. In an analysis by age group, increasing incidence was found only for 
ages 80 years and older (1990–2006). During both study periods, incidence rates were 
increasing in glioblastoma and decreasing in unspecified brain tumors. In 1990–2006, rates 
were also increasing for anaplastic oligodendroglioma, oligoastrocytoma and unspecified 
malignant glioma, while decreasing for astrocytoma. As for tumor location, incidence in 
1990–2006 was increasing for frontal lobe and brainstem tumors, as well as those with an 
unspecified location, but decreasing for the parietal lobes, cerebrum and ventricles. 
Conclusions: No increasing incidence trend was observed for malignant gliomas overall. An 
increasing incidence trend of malignant gliomas was found in the oldest age group during 
1990–2006. 
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Introduction 
Gliomas comprise a heterogenous group of brain tumors originating from glial cells. They are 
the most common malignant central nervous system (CNS) tumors (80%).1 However, age-
standardized incidence rate (age-standardized to the world standard population) of malignant 
CNS tumors in Europe is 5.6/100,000 (2018 estimate), making them only the 17th most 
common cancer type.2 In Finland, the incidence rates were 5.5/100,000 for males and 
4.3/100,000 for females (2003–2007) (world standard population).3 Despite their rarity, 
malignant gliomas contribute disproportionately to cancer mortality, because of their poor 
prognosis.4 Although the prognosis of malignant glioma has improved during the recent 
decades, mortality is still very high.5, 6  
Several studies have reported increasing incidence of gliomas, especially among the elderly, 
until the early 1990’s, when the increasing trend has leveled off.7-12 The increasing incidence 
rates can be partly explained by the introduction of CT and MRI during the 1970’s and 
1980’s, resulting in detection of cases that would have remained undiagnosed earlier.13 Even 
though several recent studies have shown stable incidence,7-9, 12, 14-20 the findings have not 
been entirely consistent.5, 21-23 
Our aim is to analyze incidence trends of malignant gliomas by histological type and 
anatomic location using data from a well-established, high-quality cancer registry with 
nationwide coverage.  
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Materials and Methods 
Data sources 
The data for the study were obtained from the Finnish Cancer Registry (FCR) on all primary 
malignant brain tumors (ICD-O-3 morphology codes 9380–9451) and unspecified malignant 
brain tumors (ICD-O-3 morphology code 8000) diagnosed during 1990–2006. The cancer 
registry data covered date of diagnosis, primary site, histological type, malignancy and any 
previous cancers. Sex and age of the patient were reported, but no personal identifiers (or 
date of birth) were obtained. Data on population size by age, gender and calendar year for 
calculation of incidence rates were obtained from Statistics Finland.24 
The histological (morphology) classification of brain tumors used at FCR prior to 2008 was 
very crude and did not comply with ICD-O. Therefore, detailed histological type, grading, 
and location of the tumor were abstracted from the text fields in the cancer notifications  
(altogether 9,389 clinical notifications and 13,217 laboratory notifications on 5,638 unique 
cancer patients during 1990–2006, including subsequently excluded cases). In Finland, 
unique personal identification codes have been widely used since the late 1960’s. They allow 
unequivocal identification (barring errors) and are used for elimination of duplicate records 
and for deterministic record linkage. 
Based on the detailed diagnostic information in the text fields of the cancer registry 
notifications, tumor histological type and anatomic site were systematically reclassified 
according to ICD-O-3.25 Clinical notifications were primarily used to define tumor location 
and laboratory notifications for morphology. If multiple histological types were mentioned in 
synchronous cancer notifications for the same patient, the more specific and more malignant 
type was used. If the subsequent notification was issued at least one week later, the earliest 
notification was used in order to avoid classifying cases into more malignant phenotype due 
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to progression after the initial diagnosis. However, if a pathologist had corrected the 
diagnosis within a week, the later notification was used (assuming that e.g. the initial 
diagnosis was based on a perioperative of fresh tissue and the latter on additional stainings 
and more comprehensive evaluation). Multiple primaries were identified based on the code 
assigned by the cancer registry. 
In addition, we obtained the most recent data on primary malignant brain tumors from the 
FCR diagnosed during 2007–2016. This data was not as detailed as that abstracted from the 
notifications, but consisted only of frequencies of cases by year, sex, age group and 
histological type, and therefore we could not perform as detailed analyses as from the data 
coded by ourselves. We also obtained frequencies of cases diagnosed based on death 
certificate only from the FCR during 1990–2016. The proportion of microscopically verified 
cases in the earlier study period was estimated by assuming that the case was microscopically 
verified if the patient had at least one laboratory notification.  
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Classification and exclusion criteria 
We focused on adult primary malignant gliomas in the brain (ICD-O-3 topography code 
C71). Patients younger than 20 years were excluded, because brain tumors in children and 
adolescents are biologically different from adults,1, 26 and we wanted to focus on a 
homogenous tumor entity. Benign (grade I) brain tumors according to the 2007 WHO 
classification of CNS tumors27 were also excluded. If the initial histological type was 
subsequently reclassified as other than malignant glioma, the tumor was excluded. Table 1 
shows subtypes of malignant glioma included in our study. Unspecified brain tumors (ICD-
O-3 morphology code 8000 with topography code C71) were included as a separate category. 
Primary site of origin was defined based on ICD-O-3 topography classification. Cases with 
two locations (for example frontotemporal) were classified as reported for the most common 
combinations (subsites that comprised over one percent of all tumors). If three or more 
locations were reported, the location was classified as overlapping. Uncommon site 
combinations (subsites with two locations comprising less than one percent of all tumors) 
were combined as ‘other specified locations’.  
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Statistical analyses  
We calculated age-standardized incidence rates (ASR) with 95% confidence intervals (CI) for 
all tumors combined, by gender, calendar year, histological type and anatomic location using 
the 2013 European standard population.28 Age-specific incidence rates were calculated for 
10-year age groups. Crude incidence rates from the most recent data (2007–2016) were 
calculated and used for incidence trend analyses. We also obtained ASR for all tumors 
combined and by gender and histological type for 2007–2016, but not detailed enough data 
for analyses of incidence trend by age group or gender. 
Age- and gender-adjusted incidence trends for each histological subtype and location were 
analyzed using Poisson regression, with number of cases as the outcome and population size 
as the offset term to estimate the average annual percent change (APC) in incidence rate. 
Mutually adjusted gender- and age group-specific incidence trends were also analyzed for 
1990–2006. For incidence trend analyses, we used the classification principles presented 
above, with the exception that we assigned cases with two locations by dividing a half case to 
both locations. Thereby, only ICD-O-3 codes C71.0–C71.9 were used for incidence trend 
analyses. In addition, we calculated the proportion of microscopically verified cases and 
death certificate only cases during the study period and conducted trend analyses to evaluate 
any change over time. 
We investigated whether the incidence trend deviated from linearity by adding calendar year 
of diagnosis as a categorical variable to the Poisson regression model containing a linear term 
for year, with a significant categorical term indicating a departure from linearity. In addition, 
we further investigated the possible deviation from linearity by adding squared year term as a 
continuous variable to the Poisson regression model. We also analyzed whether the incidence 
trends differed significantly between subgroups defined by gender, age group, histological 
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type or anatomic location by adding an interaction term (the product of year and gender, and 
in a separate analysis of year and age group, year and histological type or year and anatomic 
location) to the Poisson regression model for the years 1990–2006, and used the likelihood 
ratio test to compare the goodness of fit of the two nested models. In a sensitivity analysis, 
we evaluated whether distributing unspecified malignant gliomas and unspecified tumors of 
the brain to the specific histological subtypes by the percentage of each subtype (assuming 
the information was missing at random) affected the incidence trends. Statistical analyses 
were performed using Stata (version 15.1) and Microsoft Excel (version 16.0).  
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Results 
Between 1990 and 2006, 4,730 malignant glioma cases in adults were reported to the FCR 
and 3,590 cases in 2007–2016. The ASR of all gliomas combined was 7.7/100,000 (95% CI: 
7.5–7.9/100,000) in 1990–2006 (Table 2) and 7.3/100,000 in 2007–2016 (Table 3). Of the 
diagnoses during 1990–2006, 77.7% were microscopically verified. During 1990–2016, 
12.4% of the diagnoses were based on death certificate only. The proportion of cases 
diagnosed based on death certificate only did not change markedly over time (APC: −0.7%; 
95% CI: −1.6, +0.0). However, the proportion of microscopically verified cases decreased 
slightly (APC: −0.9%; 95% CI: −1.6, −0.3). 
Gliomas were more common in men (4,506 cases, 54.2%), with an ASR of 9.3/100,000 (95% 
CI: 8.9–9.6/100,000) in 1990–2006 and 8.6/100,000 in 2007–2016. In women, the ASR was 
6.5/100,000 (95% CI: 6.3–6.8/100,000) in 1990–2006 and 6.1/100,000 in 2007–2016. During 
the earlier study period, most malignant gliomas were diagnosed in the age group 60–69 
years (1,026 cases, 21.7%), but the highest age-specific incidence rate was in the ages 70–79 
years (15.2/100,000; 95% CI: 14.2–16.2/100,000). Incidence increased with age at an average 
rate of 37.6% (95% CI: +35.4, +39.9) increment per each decade of age. 
Astrocytic tumors comprised 67.5% of all gliomas, and glioblastoma was the most common 
histological subtype (4,060 cases, 48.8%), ASR being 3.8/100,000 (95% CI: 3.7–
4.0/100,000) in 1990–2006 and 3.5/100,000 in 2007–2016 (Table 2 and Table 3). 
Unspecified tumors of the brain comprised 12.5% of all tumors (590 cases) in 1990–2006 and 
16.5% in 2007–2016 (592 cases). 
Most malignant gliomas diagnosed in 1990–2006 were located in the cerebral lobes (73.4%) 
(Table 4). Frontal lobe was the most common location with 1,108 cases (23.4%), ASR being 
1.7/100,000 (95% CI: 1.6–1.8/100,000). Temporal lobe was almost as common with 969 
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cases (20.5%), and an ASR of 1.6/100,000 (95% CI: 1.5–1.7/100,000). Tumors with an 
unspecified location comprised 11.2% of all gliomas. 
Overall, the ASR of gliomas was stable during 1990–2006 (Figure 1). The APC in the 
incidence rate of all gliomas was close to zero (APC: +0.1%; 95% CI: −0.5, +0.7) (Table 2). 
In addition, there was no indication of deviation from linearity, i.e. no evidence of change in 
the overall incidence trend during the study period (likelihood ratio test with year as a 
categorical variable p = 0.19; likelihood ratio test with squared year term as a continuous 
variable p = 0.61). No clear trend was observed in incidence rates of gliomas during 2007–
2016 either (APC: −0.5%; 95% CI: −1.7, +0.7; Supplementary Figure 1). 
Graphical presentation of the annual incidence rates by gender showed no difference in 
incidence trends between genders in 1990–2006 (Figure 2), which was also confirmed using 
an interaction term in Poisson regression analysis (likelihood ratio test p = 0.33). A difference 
in incidence trends between the age groups was observed, when tested using an interaction 
term in Poisson regression analysis (likelihood ratio test p = 0.001). However, the only 
significant increase in incidence rates was in the oldest age group (80+ years), with an APC 
of +4.8% (95% CI: +2.6, +7.0) (Table 2). 
A difference in incidence trends between histological types during 1990–2006 was evident 
(likelihood ratio test p < 0.001). The incidence trend of glioblastoma was slightly increasing 
(APC: +0.8%; 95% CI: −0.0, +1.7 for 1990–2006 and +1.9%; 95% CI: +0.2, +3.5 for 2007–
2016; Table 2 and Table 3). A decreasing ASR was found for unspecified tumors of the brain 
(APC: −4.5%; 95% CI: −6.0, −2.9 for 1990–2006 and −6.0%; 95% CI: −8.6, −3.3 for 2007–
2016), whereas incidence of unspecified malignant glioma increased by +6.7% per year (95% 
CI: +2.6, +11.0) ) in 1990–2006 and at a nearly identical rate in 2007–2016. Incidence of 
oligoastrocytoma increased in 1990–2006 (APC: +6.6%; 95% CI: +3.8, +9.5), but not any 
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more during the later period. During the earlier study period, significant increase in ASRs 
was also observed for anaplastic oligodendroglioma (APC: +6.0%; 95% CI: +2.3, +9.8), 
while incidence trend of astrocytoma showed a decrease of −2.8% per year (95% CI: −4.4, 
−1.1). Incidence of anaplastic astrocytoma increased in 2007–2016 (APC: +7.3%; 95% CI: 
+2.2, +12.7). In addition, imputing specific histologic types (in similar proportion to those 
with known cell type) to unspecified tumors had no substantial effect on the incidence trends 
in 1990–2006 (see Supplementary Table 1). 
We also found a difference in incidence trends between anatomic locations during 1990–2006 
(likelihood ratio test p < 0.001). Incidence trends were increasing for the frontal lobe (APC: 
+1.7%; 95% CI: +0.6, +2.8), brainstem (APC: +5.8%; 95% CI: +1.7, +10.0) and unspecified 
locations (APC: +2.3%; 95% CI: +0.5, +4.1) (Table 4). Trends were decreasing for the 
parietal lobes (APC: −2.4%; 95% CI: −4.0, −0.9), cerebrum (APC: −3.5%; 95% CI: −6.2, 
−0.7) and ventricles (APC: −6.0%; 95% CI: −10.4, −1.4).  
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Discussion 
In analyses of the incidence trends of adult malignant gliomas in Finland during 1990–2016, 
we found no increase for gliomas overall. Also, there was no difference in incidence trends 
between the genders. Incidence rates in the oldest age group (80+ years) increased throughout 
the earlier study period (1990–2006), while younger age groups showed no such increase. 
Incidence of glioblastoma increased slightly throughout the study period, while unspecified 
tumors of the brain showed a decreasing incidence trend. During 1990–2006, significant 
increases were observed for anaplastic oligodendroglioma, oligoastrocytoma and unspecified 
malignant glioma, whereas incidence of astrocytoma decreased. In addition, incidence of 
anaplastic astrocytoma increased in 2007–2016. Incidence rates for tumors in the frontal lobe, 
brainstem and unspecified location increased throughout the earlier study period. In contrast, 
tumor incidence decreased in the parietal lobes, cerebrum and ventricles. 
Our results are consistent with most recent studies.7-9, 12, 14-20, 29 Some studies have reported 
increasing trends in young adults in their 20s,7, 19 but increasing trends have been more 
commonly found in the oldest age groups7, 9, 11, 12, 14, 20-23, 29, 30 similar to our results. We also 
found a slightly increasing incidence trend for the most common histological subtype, 
glioblastoma, which is consistent with several other studies.1, 5, 7-9, 11, 17, 18 A study from 
United States showed an increasing incidence trend for gliomas in the frontal lobe and 
decreasing trends for the cerebrum, ventricles and overlapping subtypes.17 Our findings were 
comparable otherwise, but we also found a decreasing trend for tumors in the parietal lobes 
and an increasing trend for brainstem tumors. 
The overall age-standardized incidence rate of all gliomas in our study was 7.7/100,000 in 
1990–2006 and 7.3/100,000 in 2007–2016, which is relatively high compared to other 
studies. A Finnish study reported incidence rate of 4.7/100,000 for all gliomas, but it was 
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based on only 331 cases, and analyses were mainly focused on anatomic locations of brain 
tumors.31 Cancer Incidence in Five Continents (CI5) Volume X reports incidence rates for 
brain and CNS tumors of 7.7/100,000 (adjusted to the world standard population) for Finnish 
men aged 20+ and 5.9/100,000 for females (2003–2007).3 Incidence rates of malignant 
gliomas comparable to ours were reported from Northwestern England (7.2/100,000; adjusted 
to the European standard population).16 A Danish study also reported quite similar incidence 
of gliomas (7.3/100,000; including grade I tumors, which comprised only 2.1% of all 
tumors).32 However, their rates for glioblastoma were higher than in our study (5.1/100,000 
vs. 3.8/100,000). Several studies have reported lower incidence rates,8, 15 which may be partly 
attributable to inclusion of children or non-Caucasian ethnic groups, or incomplete case 
ascertainment. A number of studies have also reported similar or higher incidence rates, but 
they have covered either all CNS tumors or benign brain tumors, and are therefore not 
comparable.5, 7, 14, 22 
One possible explanation for the increasing incidence in the oldest age group is improvement 
in diagnostics. Availability of MRI and CT scans has increased the use of these diagnostic 
methods. Besides increasing the overall incidence, more frequent use of MRI imaging may 
have affected particularly the diagnosis of brain stem tumors, which are better visualized with 
MRI than with CT. More active treatment of brain tumors in elderly patients has probably 
improved the detection and diagnostic accuracy of cases in age groups older than 60–70 
years, as it has likely increased both biopsies and resections, and hence specific diagnoses. 
Unspecified brain tumors decreased during the study period and therefore some of the 
specific histological subtypes must have increased simply owing to more accurate diagnostics 
including modern immunohistochemistry, i.e. cases earlier assigned as unspecified were 
classified more accurately in more recent years. An increase in unspecified malignant 
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gliomas simultaneously with a decrease in unspecified tumors of unknown malignancy could 
be explained by increased diagnosis based on imaging only. The increase in unspecified 
malignant gliomas was of similar magnitude in relative terms, but corresponds to smaller 
numbers of cases due to smaller frequencies. In contrast, tumors with unspecified location 
increased, which slightly decreased incidence rates in some specific locations. There was no 
clear change in proportions of microscopically confirmed cases or death certificate only cases 
during the study period. 
Very few countries have a comprehensive, well-established nationwide population-based 
cancer registry with multiple sources of information and documented completeness of 
coverage. In Finland, cancer incidence data have been collected by the FCR since 1953, and 
notification of cancer cases to the registry has been mandatory since 1961. Case notifications 
are received from hospitals, health care professionals, pathology laboratories and Statistics 
Finland’s cause of death data.33 The data received from different sources are then compared 
and double-checked to verify the accuracy of every diagnosis. Furthermore, the unique 
personal identification number allows elimination of duplicate records. Therefore, our data 
based on the FCR is very comprehensive and reliable. In addition, we abstracted information 
from every report for each case and reclassified histological type and anatomic site of 
presentation according to ICD-O-3 to improve the accuracy and comparability of the 
classification. 
Finland has centralized the treatment of malignant brain tumors into five university hospitals, 
which makes diagnoses very standardized and consistent, thus improving also the reliability 
of the data at the FCR. Also, there were no major changes in brain tumor classification during 
our study period, ensuring consistency of data throughout the study period. 
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Our study had also some limitations. Re-evaluation of the tumor slides by an experienced 
neuropathologist would have further improved the accuracy and reliability of the diagnoses, 
but this is not feasible in a large population-based study. Therefore, we could not 
retrospectively apply the recent 2016 WHO classification of CNS tumors. Our systematic 
reclassification and detailed analyses did not cover the most recent years but focused on the 
time period with insufficient detail of tumor classification at the cancer registry. The tabular 
data for the later period did not allow detailed analyses of trend in 2007-2016. Also, the 
number of cases in several subgroups was fairly small, limiting the precision of the estimates. 
We did not conduct join-point analyses, as the incidence rates were very flat. 
There are also some limitations concerning the systematic reclassification process. Some 
patients had discrepancies in diagnoses between cancer notifications, making it difficult to 
define the correct diagnosis. Also, incomplete information in cancer notifications may have 
affected the results by inducing misclassification.  
The stable incidence rates of malignant gliomas suggest no major increase in public exposure 
to major risk factors. Although usage of mobile phones increased dramatically during our 
study period, overall incidence rates of malignant gliomas did not increase at all. 
Furthermore, we observed no increasing incidence rates in the temporal lobes, which are the 
most exposed part of the brain from the radiofrequency electromagnetic fields emitted by 
mobile phones. 
The recently updated 2016 WHO classification of tumors of the CNS is the first to use 
molecular and genetic parameters besides histological features to define several CNS tumor 
entities including malignant gliomas. In the present study, the increase in oligodendroglial 
tumor incidence and the decrease of astrocytoma incidence might be due to the introduction 
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of the chromosome 1p/19q-analysis in the diagnosis of oligodendrogliomas in the early 
2000s.34 
Further studies are necessary to evaluate the impact of the new WHO classification system, 
and to determine the most recent incidence rates. Also, if the latency between radiofrequency 
field exposure and tumor development is very long, future studies with more recent data 
assessing longer exposure and latency periods will be needed. 
In conclusion, no increase in adult malignant gliomas overall was found for Finland in 1990–
2016. However, an increase in the oldest age group during 1990–2006 was observed, 
comparable to several other populations. An increase in glioblastoma was accompanied by a 
decrease in unspecified tumors, complicating the interpretation of trends in specific tumor 
types.  
17 
 
Acknowledgments 
We thank Ms. Katja Kuukka for her instrumental contribution in abstracting the data from the 
cancer registry notifications, Heini Huhtala, MSc, for her contribution to data analysis, 
Joonas Haapasalo, MD, PhD, for clinical advice and Aapeli Nevala, BSc from the Finnish 
Cancer Registry for assistance with the data. This study was financially supported by the 
Competitive State Research Financing of the Expert Responsibility area of Tampere 
University Hospital [#9U001]. 
Disclosure of interest 
The authors report no conflicts of interest. 
Ethics statement 
Our study follows the principles of the Declaration of Helsinki.  
References 
1. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: Primary brain and 
other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro 
Oncol. 2017;19(suppl_5):v1–v88. 
2. Ferlay J, Ervik M, Lam F, et al. (2018). Global Cancer Observatory: Cancer Today. Lyon, 
France: International Agency for Research on Cancer. Available from: 
https://gco.iarc.fr/today, accessed 15/3/2019. 
3. Forman D, Bray F, Brewster DH, et al. (2013). Cancer 
Incidence in Five Continents, Vol. X (electronic version). 
Lyon: International Agency for Research on Cancer. Available from: http://ci5.iarc.f, 
accessed 15/3/2019. 
4. Rouse C, Gittleman H, Ostrom QT, et al. Years of potential life lost for brain and CNS 
tumors relative to other cancers in adults in the United States, 2010. Neuro Oncol. 
2016;18(1):70. 
5. Ho VKY, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of 
gliomas. Eur J Cancer. 2014;50(13):2309-2318. 
18 
 
6. Visser O, Ardanaz E, Botta L, et al. Survival of adults with primary malignant brain 
tumours in Europe; Results of the EUROCARE-5 study. Eur J Cancer. 2015;51(15):2231-
2241. 
7. Arora RS, Alston RD, Eden TOB, et al. Are reported increases in incidence of primary 
CNS tumours real? An analysis of longitudinal trends in England, 1979–2003. Eur J Cancer. 
2010;46(9):1607-1616. 
8. Deorah S, Lynch CF, Sibenaller ZA, et al. Trends in brain cancer incidence and survival in 
the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. 
Neurosurg focus. 2006;20(4):E1. 
9. Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 
1977–2000. Cancer. 2004;101(10):2293-2299. 
10. Deltour I, Johansen C, Auvinen A, et al. Time trends in brain tumor incidence rates in 
Denmark, Finland, Norway, and Sweden, 1974–2003. J Natl Cancer Inst. 2009;101(24):1721-
1724. 
11. Lönn S, Klaeboe L, Hall P, et al. Incidence trends of adult primary intracerebral tumors in 
four Nordic countries. Int J Cancer. 2004;108(3):450-455. 
12. Nomura E, Ioka A, Tsukuma H. Trends in the incidence of primary intracranial tumors in 
Osaka, Japan. Jpn J Clin Oncol. 2011;41(2):291-294. 
13. Helseth A. The incidence of primary CNS neoplasms before and after computerized 
tomography availability. J Neurosurg. 1995;83(6):999-1003. 
14. J‐H Kim S, Ioannides SJ, Elwood JM. Trends in incidence of primary brain cancer in 
New Zealand, 1995 to 2010. Aust N Z J Public Health. 2015;39(2):148-152. 
15. Lin Y, Chiu H, Chiou M, et al. Trends in the incidence of primary malignant brain tumors 
in Taiwan and correlation with comorbidities: A population-based study. Clin Neurol 
Neurosurg. 2017;159:72-82. 
16. Sehmer EAJ, Hall GJ, Greenberg DC, et al. Incidence of glioma in a northwestern region 
of England, 2006–2010. Neuro Oncol. 2014;16(7):971-974. 
17. Zada G, Bond AE, Wang YP, Giannotta SL, Deapen D. Incidence trends in the anatomic 
location of primary malignant brain tumors in the United States: 1992–2006. World 
Neurosurg. 2012;77(3-4):518-524. 
18. Dubrow R, Darefsky AS. Demographic variation in incidence of adult glioma by subtype, 
United States, 1992-2007. BMC Cancer. 2011;11(1):325. 
19. Inskip PD, Hoover RN, Devesa SS. Brain cancer incidence trends in relation to cellular 
telephone use in the United States. Neuro Oncol. 2010;12(11):1147-1151. 
20. Crocetti E, Trama A, Stiller C, et al. Epidemiology of glial and non-glial brain tumours in 
Europe. Eur J Cancer. 2012;48(10):1532-1542. 
19 
 
21. Dobes M, Shadbolt B, Khurana VG, et al. A multicenter study of primary brain tumor 
incidence in Australia (2000-2008). Neuro Oncol. 2011;13(7):783-790. 
22. Etxeberria J, Román ES, Burgui R, et al. Brain and central nervous system cancer 
incidence in navarre (Spain), 1973-2008 and projections for 2014. J Cancer. 2015;6(2):177-
183. 
23. Pouchieu C, Gruber A, Berteaud E, et al. Increasing incidence of central nervous system 
(CNS) tumors (2000-2012): findings from a population based registry in Gironde (France). 
BMC Cancer. 2018;18(1):653. 
24. Statistics Finland. Available from: https://www.stat.fi/index_en.html, accessed 17/7/2018. 
25. World Health Organization: International Classification of Diseases for Oncology: ICD-
O. Available from: http://codes.iarc.fr/, accessed 2/7/2018. 
26. Broniscer A, Baker SJ, West AN, et al. Clinical and molecular characteristics of 
malignant transformation of low-grade glioma in children. J Clin Oncol. 2007;25(6):682-689. 
27. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the 
central nervous system. Acta Neuropathol. 2007;114(2):97-109. 
28. Eurostat. Available from: http://ec.europa.eu/eurostat/web/main/home, accessed 
17/7/2018. 
29. Nilsson J, Järås J, Henriksson R, et al. No Evidence for Increased Brain Tumour 
Incidence in the Swedish National Cancer Register Between Years 1980-2012. Anticancer 
Res. 2019;39(2):791-796. 
30. Fuentes-Raspall R, Solans M, Roca-Barceló A, et al. Descriptive epidemiology of 
primary malignant and non-malignant central nervous tumors in Spain: Results from the 
Girona Cancer Registry (1994–2013). Cancer Epidemiology. 2017;50:1-8. 
31. Larjavaara S, Mäntylä R, Salminen T, et al. Incidence of gliomas by anatomic location. 
Neuro Oncol. 2007;9(3):319. 
32. Rasmussen BK, Hansen S, Laursen RJ, et al. Epidemiology of glioma: clinical 
characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish 
Neuro-Oncology Registry. J Neurooncol. 2017;135(3):571-579. 
33. Leinonen MK, Miettinen J, Heikkinen S, et al. Quality measures of the population-based 
Finnish Cancer Registry indicate sound data quality for solid malignant tumours. Eur J 
Cancer. 2017;77:31-39. 
34. Jenkins RB, Curran W, Scott CB, et al. Pilot evaluation of 1p and 19q deletions in 
anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group. 
Am J Clin Oncol. 2001;24(5):506-508. 
  
20 
 
Figure Legends 
Figure 1. Incidence trend of malignant gliomas in Finland 1990–2006. 
 
 
 
 
 
 
 
 
 
21 
 
Figure 2. Incidence trends of malignant gliomas by gender in Finland 1990–2006. 
 
Supplementary Figure 1. Incidence trends of malignant gliomas in Finland 2007–2016. 
 
Table 1. Brain tumor subtypes classified as malignant glioma in our study 
 
Glioma subtype Morphology code 
Astrocytic tumors  
 Astrocytoma 9400, 9411, 9420 
 Anaplastic astrocytoma 9401 
 Glioblastoma 9440–9442 
Oligodendroglial tumors  
 Oligodendroglioma 9450 
 Anaplastic oligodendroglioma 9451 
Oligoastrocytic tumors  
 Oligoastrocytoma grade II and III 9382 
Ependymal tumors  
 Ependymoma 9391, 9393 
 Anaplastic ependymoma 9392 
Unspecified malignant glioma 9380 
Other malignant tumors  
 Other specified tumors of the brain 9381, 9390, 9424, 9430, 9470, 9471, 9473, 9505 
 Unspecified tumors of the brain 
 
8000 
 
Table 2. Incidence and APC in age- and gender-adjusted incidence trends of adult malignant brain tumors by gender, age, year period and 
histological type in Finland 1990–2006 
  
Frequency 
 Age-standardized incidence 
rate (/100,000) 
  
Annual percent change 
 n %  Rate 95% CI  APC 95% CI 
Total 4,730 100.0  7.7 7.5–7.9  +0.1 −0.5, +0.7 
Gender         
 Male 2,542 53.7  9.3 8.9–9.6  −0.2 −1.0, +0.6 
 Female 2,188 46.3  6.5 6.3–6.8  +0.5 −0.4, +1.4 
Agea         
 20–29 268 5.7  2.4 2.1–2.7  −1.0 −3.3, +1.5 
 30–39 513 10.8  4.1 3.8–4.5  0.0 −1.8, +1.8 
 40–49 705 14.9  5.2 4.9–5.6  −1.1 −2.6, +0.4 
 50–59 932 19.7  8.1 7.6–8.7  +0.3 −1.0, +1.6 
 60–69 1,026 21.7  12.2 11.5–13.0  −0.5 −1.7, +0.7 
 70–79 909 19.2  15.2 14.2–16.2  +0.2 −1.2, +1.5 
 80+ 377 8.0  12.6 11.3–13.9  +4.8 +2.6, +7.0 
Year period         
 1990–1993 1,042 22.03  7.6 7.2–8.1    
 1994–1997 1,064 22.49  7.5 7.1–8.0    
 1998–2001 1,107 23.40  7.6 7.1–8.0    
 2002–2006 1,517 32.07  7.9 7.5–8.4    
Histology         
Astrocytic tumors         
 Astrocytoma 574 12.1  0.8 0.8–0.9  −2.8 −4.4, −1.1 
 Anaplastic astrocytoma 481 10.2  0.7 0.7–0.8  −0.4 −2.2, +1.4 
 Glioblastomab 2,284 48.3  3.8 3.7–4.0  +0.8 −0.0, +1.7 
Oligodendroglial tumors         
 Oligodendroglioma 215 4.5  0.3 0.3–0.3  −0.2 −2.9, +2.6 
 Anaplastic oligodendroglioma 135 2.9  0.2 0.2–0.2  +6.0 +2.3, +9.8 
Oligoastrocytic tumors         
 Oligoastrocytoma grade II and III 238 5.0  0.3 0.3–0.4  +6.6 +3.8, +9.5 
Ependymal tumors         
 Ependymoma 45 1.0  0.1 0.0–0.1  +4.2 −1.9, +10.8 
 Anaplastic ependymoma 16 0.3  0.0 0.0–0.0  −1.2 −10.6, +9.2 
Unspecified malignant glioma 111 2.3  0.2 0.2–0.2  +6.7 +2.6, +11.0 
Other malignant tumors         
 Other specified tumors of the brain 41 0.9  0.1 0.0–0.1  +3.0 −3.3, +9.7 
 Unspecified tumors of the brain 590 12.5  1.1 1.0–1.2  −4.5 −6.0, −2.9 
 
aAge-specific rates; bp = 0.053 
Statistically significant APC are in bold (p < 0.05) 
 
Table 3. Incidence and APC in incidence trends of adult malignant brain tumors in Finland 2007–2016 
 Frequency  Age-standardized 
incidence rate (/100,000) 
 Annual percent change 
 n %   APC 95% CI 
Total 3,590 100.00  7.3  −0.5 −1.7, +0.7 
Total (only specific types) 2,872 80.00  6.2  +0.9 −0.4, +2.2 
Gender        
 Men 1,964 54.71  8.6    
 Women 1,626 45.29  6.1    
Histology        
Astrocytic tumors        
 Astrocytoma 297 8.27  0.7  −2.9 −6.7, +1.0 
 Anaplastic astrocytoma 202 5.63  0.5  +7.3 +2.2, +12.7 
 Glioblastoma 1,776 49.47  3.5  +1.9 +0.2, +3.5 
Oligodendroglial tumors        
 Oligodendroglioma grade II and III 273 7.60  0.7  −3.7 −7.6, +0.4 
Oligoastrocytic tumors        
 Oligoastrocytoma grade II and III 216 6.02  0.6  −1.5 −6.5, +3.7 
Unspecified malignant glioma 108 3.01  0.2  +6.2 −1.5, +14.4 
Other malignant tumors        
 Other specified tumors of the brain 126 3.51  0.3  −3.6 −9.3, +2.4 
 Unspecified tumors of the brain 592 16.49  0.9  −6.0 −8.6, −3.3 
 
Statistically significant APC are in bold (p < 0.05) 
 
Table 4. Incidence and APC in age- and gender-adjusted incidence trends of adult malignant brain tumors by location in 
Finland 1990–2006 
  
Frequency 
 Age-standardized incidence 
rate (/100,000) 
  
Annual percent change 
 n %  Rate 95% CI  APC 95% CI 
Total 4,730 100.00  7.7 7.5–7.9  +0.1 −0.5, +0.7 
Location         
 Frontal 1,108 23.4  1.7 1.6–1.8  +1.7 +0.6, +2.8 
 Frontotemporal 272 5.8  0.4 0.4–0.5    
 Frontoparietal 
 
146 3.1  0.2 0.2–0.3    
 Temporal 969 20.5  1.6 1.5–1.7  −0.6 −1.8, +0.5 
 Temporoparietal 231 4.9  0.4 0.3–0.4    
 Temporo-occipital 
 
85 1.8  0.1 0.1–0.2    
 Parietal 395 8.4  0.6 0.6–0.7  −2.4 −4.0, −0.9 
 Parieto-occipital 
 
111 2.3  0.2 0.1–0.2    
 Occipital 152 3.2  0.3 0.2–0.3  −0.1 −2.6, +2.5 
 Cerebrum 178 3.8  0.3 0.3–0.3  −3.5 −6.2, −0.7 
 Ventricles 63 1.3  0.1 0.1–0.1  −6.0 −10.4, −1.4 
 Cerebellum 74 1.6  0.1 0.1–0.2  −3.8 −8.0, +0.5 
 Brainstem 97 2.1  0.2 0.1–0.2  +5.8 +1.7, 10.0 
 Overlapping 
 
238 5.0  0.4 0.4–0.5  +2.1 −0.6, +4.8 
 Other specified 82 1.7  0.1 0.1–0.2    
 Unspecified location 529 11.2  0.9 0.8–1.0  +2.3 +0.5, +4.1 
         
Statistically significant APC are in bold (p < 0.05) 
 
 Supplementary Table 1. APC in age- and gender-adjusted incidence trends of gliomasa by 
histological type in Finland 1990–2006  
 Annual percent change 
 APC 95% CI 
Histology   
Astrocytic tumors   
 Astrocytoma −1.8 −3.4, −0.3 
 Anaplastic astrocytoma −0.4 −2.0, +1.3 
 Glioblastoma +0.8 +0.1, +1.5 
Oligodendroglial tumors   
 Oligodendroglioma +0.1 −2.6, +2.8 
 Anaplastic oligodendroglioma +5.3 +1.9, +8.9 
Oligoastrocytic tumors   
  Oligoastrocytoma grade II and III +7.2 +4.4, +10.1 
Ependymal tumors   
 Ependymoma +4.6 −1.0, +10.6 
 Anaplastic ependymoma +0.0 −8.1, +8.8 
Other malignant tumors   
 Other specified tumors of the brain +4.4 −0.9, +10.0 
   
aSpecific histologic types imputed (in similar proportion to those with known cell type) to 
unspecified tumors 
Statistically significant APC are in bold (p < 0.05)   
